Prediabetes in Patients Receiving Tacrolimus in the First Year After Kidney Transplantation: A Prospective and Multicenter Study
Authors:
- Esteban PorriniEPEsteban Porrini
- Jose Manuel MorenoJMJose Manuel Moreno
- Antonio OsunaAOAntonio Osuna
- Rocio BenitezRBRocio Benitez
- Ildefonso LampreabeILIldefonso Lampreabe
- Juan Manuel DiazJDJuan Manuel Diaz
- Irene SilvaISIrene Silva
- Rosa DomínguezRDRosa Domínguez
- Julio Gonzalez-CotorrueloJGJulio Gonzalez-Cotorruelo
- Beatriz BayesBBBeatriz Bayes
- Ricardo LauzuricaRLRicardo Lauzurica
- Meritxell IbernonMIMeritxell Ibernon
- 27 April 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 85 (8) , 1133-1138
Abstract
Tacrolimus-based immunosuppression, the most widely used regimen in kidney transplantation, increases the risk of new onset diabetes after transplantation (NODAT). However, the prevalence, evolution and risk factors of different prediabetic alterations: impaired fasting glucose, impaired glucose tolerance, and provisional diabetes, have not been established. In this multicenter and prospective study we evaluated 154 nondiabetic kidney transplant recipients receiving tacrolimus, mycophenolate mofetil and low dose steroids. An oral glucose tolerance test was performed 3 and 12 months after transplantation and prediabetes was defined by American Diabetes Association criteria. Prediabetes was highly prevalent and showed little variation between 3 and 12 months (36% and 33%, respectively). Impaired glucose tolerance was the most frequent abnormality observed (23% and 25%, respectively) observed. In addition, 20% of recipients showed NODAT by 1 year. Multivariate analysis showed that age (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 1.004–1.14), pretransplant body mass index (OR: 1.3, CI: 1.09–1.6) and triglyceride/high density lipoprotein-cholesterol ratio, a marker of insulin resistance, (OR: 1.4, CI: 1.05–1.9) were independent risk factors for prediabetes. One in two recipients with tacrolimus-based immunosuppresion showed prediabetes or NODAT by 1 year posttransplantation when properly investigated. Older age and high pretransplant body mass index and triglyceride/high density lipoprotein-cholesterol ratio were risk factors for prediabetes. These findings may help applying early interventions to prevent the disorder.Keywords
This publication has 30 references indexed in Scilit:
- The Dynamics of Glucose Metabolism Under Calcineurin Inhibitors in the First Year After Renal Transplantation in Nonobese PatientsTransplantation, 2007
- Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus TacrolimusAmerican Journal of Transplantation, 2007
- Immunosuppression: evolution in practice and trends, 1993–2003American Journal of Transplantation, 2005
- New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and managementAmerican Journal of Kidney Diseases, 2004
- New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta-AnalysisAmerican Journal of Transplantation, 2004
- Effect of Immunosuppressive Agents on Long-Term Survival of Renal Transplant RecipientsDrugs, 2004
- High Incidence of Tacrolimus-Associated Posttransplantation Diabetes in the Korean Renal Allograft Recipients According to American Diabetes Association CriteriaDiabetes Care, 2003
- POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORSTransplantation, 2001
- SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MYCOPHENOLATE MOFETIL (MMF) IN CADAVERIC RENAL TRANSPLANT RECIPIENTS1Transplantation, 2000
- Risk for posttransplant diabetes mellitus with current immunosuppressive medicationsAmerican Journal of Kidney Diseases, 1999